Oral medication adherence predicts cyclosporine blood level variability and graft versus host disease following pediatric allogeneic hematopoietic stem cell transplant
Annals of Behavioral Medicine · 2025
DOI: 10.1093/abm/kaaf055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Behavioral Medicine, 2025. Verfasst von Kimberly L Klages und 6 weiteren Autor:innen. Beteiligte Einrichtung: Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, United States. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Cyclosporine, Immunosuppressive Agents. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
Medication adherence is vital for optimal outcomes following pediatric allogeneic hematopoietic cell transplant (HCT), but current assessment methods have limitations. Cyclosporine (CSA), an immunosuppressive drug used post-HCT, is routinely monitored in post-transplant care. Variability in CSA blood levels has been linked to adherence in other pediatric populations, and the medication level variability index (MLVI) has shown strong associations with adherence behaviors. However, its utility in assessing CSA adherence post-HCT has not been explored. This study aimed to evaluate CSA blood level variability as an objective measure of adherence and establish MLVI as a predictor of disease-related outcomes in pediatric HCT recipients.
Purpose
To investigate the utility of CSA blood level variability as a measure of medication adherence and the MLVI as a predictor of graft versus host disease (GVHD) in pediatric HCT recipients.
Method
Medical and adherence data were collected from 127 children within 90 days post-discharge. Regression analyses assessed relationships between oral CSA adherence, CSA MLVI, and the incidence and grade of acute and chronic GVHD.
Results
Greater oral CSA adherence significantly predicted increased incidence (Est. = .008, P = .001) and severity of chronic GVHD (Est. = .006, P = .023), as well as greater severity of acute GVHD (Est. = .006, P = .002). Adherence did not predict acute GVHD incidence. Higher adherence variability was associated with increased MLVI (Est. = .225, P < .001) and greater severity of both acute (Est. = .004, P = .004) and chronic GVHD (Est. = .014, P < .001), but not their incidence. Greater MLVI significantly predicted increased incidence and severity of both acute (incidence: Est. = .005, P = .001; severity: Est. = .004, P = .002) and chronic GVHD (incidence: Est. = .004, P < .001; severity: Est. = .007, P < .001).
Conclusions
Inconsistent CSA adherence significantly predicted higher CSA MLVI, which was linked to increased GVHD incidence and severity. These findings highlight the potential of MLVI as a reliable adherence measure and the importance of ongoing adherence support in pediatric HCT care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, United States.
- Department of Pediatrics, University of Cincinnati College of Medicine, 3230 Eden Ave, Cincinnati, OH 45267, United States.
- Division of Oncology, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA 19104, United States.
- Department of Psychology, St Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, United States.
- Center for Biobehavioral Health, Nationwide Children's Hospital, 700 Children's Dr, Columbus, OH 43205, United States.
- Department of Pediatrics, The Ohio State University School of Medicine, 1645 Neil Ave, Columbus, OH 43210, United States.
ORCID-Profile: Kimberly L Klages, Lisa A Schwartz
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Klages, K. L., Chardon, M. L., Schwartz, L. A., Phipps, S., Drake, S. N., Skeens, M., & Pai, A. L. (2025). Oral medication adherence predicts cyclosporine blood level variability and graft versus host disease following pediatric allogeneic hematopoietic stem cell transplant. Annals of Behavioral Medicine. https://doi.org/10.1093/abm/kaaf055
Vancouver
Klages KL, Chardon ML, Schwartz LA, Phipps S, Drake SN, Skeens M, et al. Oral medication adherence predicts cyclosporine blood level variability and graft versus host disease following pediatric allogeneic hematopoietic stem cell transplant. Annals of Behavioral Medicine. 2025. doi:10.1093/abm/kaaf055
BibTeX
@article{Klages2025,
author = {Klages, Kimberly L and Chardon, Marie L and Schwartz, Lisa A and Phipps, Sean and Drake, Sarah N and Skeens, Micah and Pai, Ahna L},
title = {Oral medication adherence predicts cyclosporine blood level variability and graft versus host disease following pediatric allogeneic hematopoietic stem cell transplant},
journal = {Annals of Behavioral Medicine},
year = {2025},
doi = {10.1093/abm/kaaf055}
}
EUVIMED